Type 1 diabetes at a crossroads!
作者信息
Cefalu William T, Tamborlane William V, Skyler Jay S
机构信息
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA
Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.
出版信息
Diabetes Care. 2015 Jun;38(6):968-70. doi: 10.2337/dc15-0615.
Abstract
摘要
相似文献
1
Type 1 diabetes at a crossroads!
Diabetes Care. 2015 Jun;38(6):968-70. doi: 10.2337/dc15-0615.
2
Changes in prevalence of diabetes over 15 years in a rural Australian population: The Crossroads Studies.
Diabetes Res Clin Pract. 2020 Dec;170:108492. doi: 10.1016/j.diabres.2020.108492. Epub 2020 Oct 8.
3
The importance of crossroads in faecal marking behaviour of the wolves (Canis lupus).
Naturwissenschaften. 2004 Oct;91(10):489-92. doi: 10.1007/s00114-004-0557-1.
4
Association between lung capacity measurements and abnormal glucose metabolism: findings from the Crossroads study.
Diabet Med. 2014 May;31(5):595-9. doi: 10.1111/dme.12346. Epub 2013 Nov 18.
5
Body mass index at the crossroads of osteoporosis and type 2 diabetes.
Korean J Intern Med. 2020 Nov;35(6):1333-1335. doi: 10.3904/kjim.2020.540. Epub 2020 Oct 28.
6
A crossroads for diabetes care?
Nat Rev Endocrinol. 2010 Mar;6(3):117. doi: 10.1038/nrendo.2010.5.
7
Clinical crossroads update: a 65-year-old man with poorly controlled type 2 diabetes mellitus.
JAMA. 1997 Sep 10;278(10):820-1. doi: 10.1001/jama.1997.03550100046031.
8
Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders.
Acta Diabetol. 2020 Sep;57(9):1117-1119. doi: 10.1007/s00592-020-01547-z. Epub 2020 Jun 12.
9
NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS.
Endocr Pract. 2017 Nov;23(11):1357-1358. doi: 10.4158/EP-2017-0135.
10
Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension.
Hypertension. 2019 Jun;73(6):1138-1149. doi: 10.1161/HYPERTENSIONAHA.118.11769.
引用本文的文献
1
Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
Acta Diabetol. 2021 Jul;58(7):869-880. doi: 10.1007/s00592-021-01686-x. Epub 2021 Mar 2.
2
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
BMJ. 2019 Apr 9;365:l1328. doi: 10.1136/bmj.l1328.
3
Glucose Control, Disease Burden, and Educational Gaps in People With Type 1 Diabetes: Exploratory Study of an Integrated Mobile Diabetes App.
JMIR Diabetes. 2018 Nov 23;3(4):e17. doi: 10.2196/diabetes.9531.
4
Low-intensity pulsed ultrasound prevents muscle atrophy induced by type 1 diabetes in rats.
Skelet Muscle. 2017 Dec 22;7(1):29. doi: 10.1186/s13395-017-0145-7.
5
Bone marrow derived stem cell therapy for type 2 diabetes mellitus.
Stem Cell Investig. 2016 Dec 6;3:87. doi: 10.21037/sci.2016.11.14. eCollection 2016.
6
Building Momentum: Taking on the Real “Issues” of Diabetes Care!
Diabetes Care. 2016 Jan;39(1):10-12. doi: 10.2337/dc15-2315.
7
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.
Curr Diabetes Rev. 2017;13(3):300-314. doi: 10.2174/1573399812666160413115655.
8
Guiding principles for diabetes care.
Diabetes Care. 2015 Oct;38(10):1955-7. doi: 10.2337/dc15-1617.
9
Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!
Diabetes Care. 2015 Jul;38(7):1177-80. doi: 10.2337/dc15-0875.
本文引用的文献
1
Pathway to artificial pancreas systems revisited: moving downstream.
Diabetes Care. 2015 Jun;38(6):1036-43. doi: 10.2337/dc15-0364.
2
Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes?
Diabetes Care. 2015 Jun;38(6):1030-5. doi: 10.2337/dc15-0079.
3
Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.
Diabetes Care. 2015 Jun;38(6):1016-29. doi: 10.2337/dc15-0090.
4
Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era.
Diabetes Care. 2015 Jun;38(6):1008-15. doi: 10.2337/dc15-0100.
5
Prevention and reversal of type 1 diabetes--past challenges and future opportunities.
Diabetes Care. 2015 Jun;38(6):997-1007. doi: 10.2337/dc15-0349.
6
Predicting type 1 diabetes using biomarkers.
Diabetes Care. 2015 Jun;38(6):989-96. doi: 10.2337/dc15-0101.
7
Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.
Diabetes Care. 2015 Jun;38(6):979-88. doi: 10.2337/dc15-0144.
8
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.
9
SGLT2 inhibitors: the latest "new kids on the block"!
Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048.
10
BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening.
Diabetes Care. 2015 Jan;38(1):150-8. doi: 10.2337/dc14-2391.
Zotero 插件